Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2022-03-22 Director's Dealing
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
DGAP-DD: Heidelberg Pharma AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'DGAP-DD: Heidelberg Pharma AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This content directly matches the definition for Director's Dealing reports, which are classified under the code DIRS.
2022-03-22 English
DGAP-DD: Heidelberg Pharma AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'DGAP-DD: Heidelberg Pharma AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This content directly matches the definition for Director's Dealing reports, which corresponds to the filing type code DIRS.
2022-03-22 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German securities law (WpHG). It details changes in voting rights percentages (28.69%) and the total number of voting rights held by specific entities (dievini Hopp BioTech holding GmbH & Co. KG, DH-LT-Investments GmbH, and Christof Hettich via 4H invest GmbH) due to the conclusion of a pool agreement. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds.
2022-03-17 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details changes in voting rights percentages (28.69%) and the conclusion of a pool agreement involving specific shareholders. This content directly aligns with the definition of reporting changes in significant share ownership thresholds, which corresponds to the Major Shareholding Notification category.
2022-03-17 English
Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117
Earnings Release Classification · 99% confidence The document is a press release dated March 10, 2022, announcing that Heidelberg Pharma received a milestone payment from its partner Magenta Therapeutics because the first patient was dosed with the drug candidate MGTA-117 in a Phase I/II study. This is a specific corporate event announcement related to drug development progress and associated financial compensation (milestone payment). It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal regulatory filing like a DEF 14A or DVA. Since it announces a specific corporate development that doesn't fit the other specialized categories (like M&A, Director's Dealing, or Capital Change), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate news announcements distributed via services like DGAP, especially when the core content is a press release about operational progress rather than a formal financial statement or shareholder vote result. Q1 2022
2022-03-10 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Notification of Major Holdings' and references German securities law (WpHG). It details the acquisition/disposal of shares with voting rights and instruments, specifically noting a change in the percentage of voting rights held by Kaijun Hu and associated entities. This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of a Major Shareholding Notification. Although the header mentions 'Voting Rights Announcements', the content structure (Sections 1 through 10 detailing share positions, ISINs, and instruments) is characteristic of a major holding disclosure, which maps best to the 'Major Shareholding Notification' category (MRQ). It is not an AGM-R, 10-K, ER, or IR. It is a specific regulatory disclosure about ownership change.
2022-03-07 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.